

# Andreas K Buck

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5481065/publications.pdf>

Version: 2024-02-01

229  
papers

13,246  
citations

17440

63  
h-index

27406

106  
g-index

241  
all docs

241  
docs citations

241  
times ranked

12750  
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 571-578.	1.6	1,275
2	Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. <i>Nature</i> , 2013, 501, 421-425.	27.8	437
3	Detection of bone metastases in patients with lung cancer: <sup>99m</sup> Tc-MDP planar bone scintigraphy, <sup>18</sup> F-fluoride PET or <sup>18</sup> F-FDG PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1807-1812.	6.4	419
4	Imaging proliferation in lung tumors with PET: <sup>18</sup> F-FLT versus <sup>18</sup> F-FDG. <i>Journal of Nuclear Medicine</i> , 2003, 44, 1426-31.	5.0	281
5	SPECT/CT. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1305-1319.	5.0	280
6	FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 1317-1323.	6.4	274
7	First-in-Human Experience of CXCR4-Directed Endoradiotherapy with <sup>177</sup> Lu- and <sup>90</sup> Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease. <i>Journal of Nuclear Medicine</i> , 2016, 57, 248-251.	5.0	201
8	Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. <i>Blood</i> , 2010, 116, 1498-1505.	1.4	196
9	<i>In vivo</i> molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. <i>EMBO Molecular Medicine</i> , 2015, 7, 477-487.	6.9	180
10	Gene silencing by adenovirus-delivered siRNA. <i>FEBS Letters</i> , 2003, 539, 111-114.	2.8	176
11	Molecular Imaging of Proliferation in Malignant Lymphoma. <i>Cancer Research</i> , 2006, 66, 11055-11061.	0.9	173
12	Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. <i>Blood</i> , 2001, 98, 565-572.	1.4	166
13	Life Expectancy Is Reduced in Differentiated Thyroid Cancer Patients $\geq$ 45 Years Old with Extensive Local Tumor Invasion, Lateral Lymph Node, or Distant Metastases at Diagnosis and Normal in All Other DTC Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 172-180.	3.6	166
14	<sup>68</sup> Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative <sup>18</sup> F-Choline-PET/CT. <i>Clinical Nuclear Medicine</i> , 2016, 41, 515-521.	1.3	165
15	<sup>3</sup> -deoxy- <sup>3</sup> -[( <sup>18</sup> F)]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. <i>Cancer Research</i> , 2002, 62, 3331-4.	0.9	162
16	F-18 NaF PET for Detection of Bone Metastases in Lung Cancer: Accuracy, Cost-Effectiveness, and Impact on Patient Management. <i>Journal of Bone and Mineral Research</i> , 2003, 18, 2206-2214.	2.8	155
17	First demonstration of 3-D lymphatic mapping in breast cancer using freehand SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1452-1461.	6.4	155
18	Structured treatment interruption in patients with alveolar echinococcosis. <i>Hepatology</i> , 2004, 39, 509-517.	7.3	153

#	ARTICLE	IF	CITATIONS
19	Early Response Assessment Using $3\beta\text{-}^2\text{-Deoxy-}3\beta\text{-}^2\text{-[18F]Fluorothymidine}$ -Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2007, 13, 3552-3558.	7.0	151
20	Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in $68\text{Ga-DOTA}^2\text{TOC}$ PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 48-52.	6.4	146
21	Early Metabolic Response Evaluation by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Allows <i>in vivo</i> Testing of Chemosensitivity in Gastric Cancer: Long-term Results of a Prospective Study. <i>Clinical Cancer Research</i> , 2008, 14, 2012-2018.	7.0	140
22	$^{68}\text{Ga}$ Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to $^{18}\text{F}$ FDG and laboratory values. <i>Theranostics</i> , 2017, 7, 205-212.	10.0	138
23	$3\text{'-[18F]fluoro-3\text{'-deoxythymidine (}^{18}\text{F-FLT)}$ as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. <i>Cancer Research</i> , 2003, 63, 2681-7.	0.9	128
24	Biodistribution and Radiation Dosimetry for a Probe Targeting Prostate-Specific Membrane Antigen for Imaging and Therapy. <i>Journal of Nuclear Medicine</i> , 2015, 56, 855-861.	5.0	122
25	Progressive gait ataxia following deep brain stimulation for essential tremor: adverse effect or lack of efficacy?. <i>Brain</i> , 2016, 139, 2948-2956.	7.6	119
26	Clinical Applications of FDG PET and PET/CT in Head and Neck Cancer. <i>Journal of Oncology</i> , 2009, 2009, 1-13.	1.3	118
27	$^{18}\text{F}$ -Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging. <i>Theranostics</i> , 2020, 10, 1-16.	10.0	117
28	Imaging Gastric Cancer with PET and the Radiotracers $^{18}\text{F-FLT}$ and $^{18}\text{F-FDG}$ : A Comparative Analysis. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1945-1950.	5.0	113
29	Positron Emission Tomography (PET) for Staging of Solitary Plasmacytoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2003, 18, 841-845.	1.0	110
30	Biodistribution and Radiation Dosimetry for the Chemokine Receptor CXCR4-Targeting Probe $^{68}\text{Ga-Pentixafor}$ . <i>Journal of Nuclear Medicine</i> , 2015, 56, 410-416.	5.0	108
31	$68\text{Ga-DOTA}^2\text{TATE}$ PET/CT for the detection of inflammation of large arteries: correlation with $^{18}\text{F-FDG}$ , calcium burden and risk factors. <i>EJNMMI Research</i> , 2012, 2, 52.	2.5	107
32	CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma. <i>Theranostics</i> , 2017, 7, 1589-1597.	10.0	102
33	Clinical relevance of imaging proliferative activity in lung nodules. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 525-533.	6.4	101
34	Influence of $^{11}\text{C-choline}$ PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer. <i>Radiotherapy and Oncology</i> , 2011, 99, 193-200.	0.6	101
35	CXCR4-directed theranostics in oncology and inflammation. <i>Annals of Nuclear Medicine</i> , 2018, 32, 503-511.	2.2	98
36	Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches. <i>Journal of Nuclear Medicine</i> , 2010, 51, 401-412.	5.0	95

#	ARTICLE	IF	CITATIONS
37	Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients. <i>Neuro-Oncology</i> , 2014, 16, 603-609.	1.2	94
38	Automated Whole-Body Bone Lesion Detection for Multiple Myeloma on <sup>68</sup> Ga-Pentixafor PET/CT Imaging Using Deep Learning Methods. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-11.	0.8	93
39	<sup>188</sup> Re or <sup>90Y</sup> -labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase III study. <i>British Journal of Haematology</i> , 2005, 130, 604-613.	2.5	92
40	[ <sup>68</sup> Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer - initial experience. <i>Oncotarget</i> , 2016, 7, 9288-9295.	1.8	92
41	<sup>68</sup> Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma. <i>Theranostics</i> , 2016, 6, 428-434.	10.0	91
42	Biological characterisation of breast cancer by means of PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, S80-S87.	6.4	90
43	Comparison of the Amino Acid Tracers <sup>18</sup> F-FET and <sup>18</sup> F-DOPA in High-Grade Glioma Patients. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1611-1616.	5.0	90
44	[ <sup>11</sup> C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. <i>World Journal of Urology</i> , 2009, 27, 619-625.	2.2	89
45	Impact of <sup>11</sup> C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2222-2231.	6.4	86
46	Imaging of myocardial inflammation with somatostatin receptor based PET/CT – A comparison to cardiac MRI. <i>International Journal of Cardiology</i> , 2015, 194, 44-49.	1.7	86
47	[ <sup>177</sup> Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent. <i>Theranostics</i> , 2017, 7, 2350-2362.	10.0	84
48	Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach. <i>Theranostics</i> , 2017, 7, 1489-1498.	10.0	82
49	Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches. <i>Journal of Nuclear Medicine Technology</i> , 2010, 38, 6-17.	0.8	81
50	<sup>11</sup> C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement. <i>Theranostics</i> , 2016, 6, 254-261.	10.0	80
51	Clinical Value of 18-Fluorine-Fluorodihydroxyphenylalanine Positron Emission Tomography/Computed Tomography in the Follow-Up of Medullary Thyroid Carcinoma. <i>Thyroid</i> , 2010, 20, 527-533.	4.5	78
52	Impact of <sup>68</sup> Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy. <i>EJNMMI Research</i> , 2016, 6, 78.	2.5	78
53	Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. <i>Hypertension</i> , 2018, 71, 317-325.	2.7	77
54	Specific somatostatin receptor II expression in arterial plaque: <sup>68</sup> Ga-DOTATATE autoradiographic, immunohistochemical and flow cytometric studies in apoE-deficient mice. <i>Atherosclerosis</i> , 2013, 230, 33-39.	0.8	75

#	ARTICLE	IF	CITATIONS
55	Dopaminergic dysfunction in attention deficit hyperactivity disorder (ADHD), differences between pharmacologically treated and never treated young adults: A 3,4-dihydroxy-6-[18F]fluorophenyl-L-alanine PET study. <i>NeuroImage</i> , 2008, 41, 718-727.	4.2	73
56	Pasotuzumab, a BiTE <sup>®</sup> immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings. <i>Immunotherapy</i> , 2021, 13, 125-141.	2.0	72
57	Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. <i>Radiation Oncology</i> , 2012, 7, 99.	2.7	71
58	[131I]Iodometomidate for Targeted Radionuclide Therapy of Advanced Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 914-922.	3.6	70
59	Imaging Bone and Soft Tissue Tumors with the Proliferation Marker [18F]Fluorodeoxythymidine. <i>Clinical Cancer Research</i> , 2008, 14, 2970-2977.	7.0	69
60	Assessment of disease activity in alveolar echinococcosis: a comparison of contrast-enhanced ultrasound, three-phase helical CT and [18F]fluorodeoxyglucose positron-emission tomography. <i>Abdominal Imaging</i> , 2007, 32, 730-736.	2.0	68
61	First Demonstration of Leukemia Imaging with the Proliferation Marker <sup>18</sup> F-Fluorodeoxythymidine. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1756-1762.	5.0	68
62	Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics. <i>Theranostics</i> , 2018, 8, 369-383.	10.0	68
63	Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours. <i>Journal of Internal Medicine</i> , 2006, 260, 545-550.	6.0	67
64	Impact of moderate <i>vs</i> stringent TSH suppression on survival in advanced differentiated thyroid carcinoma. <i>Clinical Endocrinology</i> , 2012, 76, 586-592.	2.4	67
65	Predictive Value of Initial <sup>18</sup> F-FLT Uptake in Patients with Aggressive Non-Hodgkin Lymphoma Receiving R-CHOP Treatment. <i>Journal of Nuclear Medicine</i> , 2011, 52, 690-696.	5.0	65
66	<sup>11</sup> C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions. <i>Theranostics</i> , 2017, 7, 2956-2964.	10.0	63
67	Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1775-1782.	6.4	62
68	Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 484-493.	6.4	62
69	Cost-Effectiveness of Hybrid PET/CT for Staging of Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1668-1675.	5.0	62
70	Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2019, 60, 60-64.	5.0	62
71	Positron detection for the intraoperative localisation of cancer deposits. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1534-1544.	6.4	60
72	Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients. <i>Clinical Nuclear Medicine</i> , 2017, 42, e29-e34.	1.3	60

#	ARTICLE	IF	CITATIONS
73	Combined [18F]DPA-714 micro-positron emission tomography and autoradiography imaging of microglia activation after closed head injury in mice. <i>Journal of Neuroinflammation</i> , 2016, 13, 140.	7.2	59
74	The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?. <i>Theranostics</i> , 2018, 8, 6088-6100.	10.0	59
75	Salvage Treatment with Amphotericin B in Progressive Human Alveolar Echinococcosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3586-3591.	3.2	58
76	Molecular Imaging of Proliferation and Glucose Utilization: Utility for Monitoring Response and Prognosis after Neoadjuvant Therapy in Locally Advanced Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2011, 18, 3316-3323.	1.5	58
77	Targeting P-Selectin by Gallium-68â€“Labeled Fucoidan Positron Emission Tomography for Noninvasive Characterization of Vulnerable Plaques. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1661-1667.	2.4	58
78	SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1085-1091.	5.0	58
79	[68Ga]Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression After Myocardial Infarction. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 1466-1468.	5.3	56
80	18FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation. <i>Oncotarget</i> , 2014, 5, 7381-7391.	1.8	56
81	Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity. <i>Oncotarget</i> , 2017, 8, 7039-7049.	1.8	54
82	Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1355-1364.	6.4	53
83	Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging. <i>BMC Cancer</i> , 2014, 14, 268.	2.6	51
84	Imaging of Proliferation in Hepatocellular Carcinoma with the In Vivo Marker <sup>18</sup> F-Fluorothymidine. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1441-1447.	5.0	49
85	Molecular imaging of proliferation in vivo: Positron emission tomography with [18F]fluorothymidine. <i>Methods</i> , 2009, 48, 205-215.	3.8	49
86	DNA Damage in Peripheral Blood Lymphocytes of Thyroid Cancer Patients After Radioiodine Therapy. <i>Journal of Nuclear Medicine</i> , 2016, 57, 173-179.	5.0	49
87	CXCR4-targeted theranostics in oncology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4133-4144.	6.4	48
88	Focal uptake of 68Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 2005-2013.	6.4	47
89	Functional Characterization of Adrenal Lesions Using [123I]IMTO-SPECT/CT. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1508-1518.	3.6	47
90	CXCR4-Directed Imaging in Solid Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 770.	2.8	47

#	ARTICLE	IF	CITATIONS
91	[123I]Iodometomidate Imaging in Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2755-2764.	3.6	45
92	Chemokine receptor $\alpha$ Directed imaging and therapy. <i>Methods</i> , 2017, 130, 63-71.	3.8	45
93	Imaging Inflammation in Atherosclerosis with CXCR4-Directed <sup>68</sup> Ga-Pentixafor PET/CT: Correlation with <sup>18</sup> F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2020, 61, 751-756.	5.0	45
94	<sup>18</sup> F-Fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma. <i>Cancer</i> , 2013, 119, 1227-1234.	4.1	44
95	Intraoperative 3-D imaging improves sentinel lymph node biopsy in oral cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2257-2264.	6.4	44
96	Imaging Proliferation to Monitor Early Response of Lymphoma to Cytotoxic Treatment. <i>Molecular Imaging and Biology</i> , 2008, 10, 349-355.	2.6	42
97	In Vivo Characterization of Proliferation for Discriminating Cancer from Pancreatic Pseudotumors. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1437-1444.	5.0	42
98	PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1284-1288.	6.4	42
99	Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT. <i>BMC Cancer</i> , 2015, 15, 1002.	2.6	42
100	Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2122-2130.	6.4	42
101	Imaging of C-X-C Motif Chemokine Receptor CXCR4 Expression After Myocardial Infarction With [68Ga]Pentixafor-PET/CT in Correlation With Cardiac MRI. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1541-1543.	5.3	42
102	Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy. <i>Oncotarget</i> , 2016, 7, 20033-20040.	1.8	41
103	Prognostic value of positron emission tomography-assessed tumor heterogeneity in patients with thyroid cancer undergoing treatment with radiopeptide therapy. <i>Nuclear Medicine and Biology</i> , 2015, 42, 349-354.	0.6	40
104	Triplex-forming oligodeoxynucleotides targeting survivin inhibit proliferation and induce apoptosis of human lung carcinoma cells. <i>Cancer Gene Therapy</i> , 2003, 10, 403-410.	4.6	39
105	Myeloablative Radioimmunotherapy with Re-188-anti-CD66-Antibody for Conditioning of High-Risk Leukemia Patients Prior to Stem Cell Transplantation: Biodistribution, Biokinetics and Immediate Toxicities. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2002, 17, 151-163.	1.0	38
106	<sup>11</sup> C-Methionine-PET: A novel and sensitive tool for monitoring of early response to treatment in multiple myeloma. <i>Oncotarget</i> , 2015, 6, 8418-8429.	1.8	38
107	Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1415-1421.	5.0	38
108	FLT-PET Is Superior to FDG-PET for Very Early Response Prediction in NPM-ALK-Positive Lymphoma Treated with Targeted Therapy. <i>Cancer Research</i> , 2012, 72, 5014-5024.	0.9	37



#	ARTICLE	IF	CITATIONS
109	Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications. <i>Annals of Nuclear Medicine</i> , 2018, 32, 512-522.	2.2	37
110	Side Effects of CXC-Chemokine Receptor 4-Directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell Transplantation. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1399-1405.	5.0	37
111	Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 807-815.	2.1	36
112	Internal radionuclide therapy: The ULMDOS software for treatment planning. <i>Medical Physics</i> , 2005, 32, 2399-2405.	3.0	36
113	Clinical Value and Limitations of [11C]-Methionine PET for Detection and Localization of Suspected Parathyroid Adenomas. <i>Molecular Imaging and Biology</i> , 2009, 11, 356-363.	2.6	36
114	<sup>18</sup> F-FDG PET Detects Inflammatory Infiltrates in Spinal Cord Experimental Autoimmune Encephalomyelitis Lesions. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1269-1276.	5.0	36
115	Lymph Node Staging in Lung Cancer Using [18F]FDG-PET. <i>Thoracic and Cardiovascular Surgeon</i> , 2004, 52, 96-101.	1.0	35
116	[18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 34-43.	6.4	35
117	Freehand SPECT-guided sentinel lymph node biopsy in early oral squamous cell carcinoma. <i>Head and Neck</i> , 2014, 36, E112-6.	2.0	35
118	CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1765-1771.	5.0	34
119	[ 18 F] 3-deoxy-3- <sup>2</sup> -fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[ 18 f]-fluoro-2-deoxy- d -glucose positron emission tomography in the workup of suspicious central focal lesions?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2004, 127, 1093-1099.	0.8	33
120	The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2281-2290.	6.4	32
121	Facing the Nuclear Threat: Thyroid Blocking Revisited. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 3511-3516.	3.6	31
122	Tumor-Associated Macrophages in Glioblastoma Multiforme- A Suitable Target for Somatostatin Receptor-Based Imaging and Therapy?. <i>PLoS ONE</i> , 2015, 10, e0122269.	2.5	31
123	Comparison of 11C-Choline and 11C-Methionine PET/CT in Multiple Myeloma. <i>Clinical Nuclear Medicine</i> , 2019, 44, 620-624.	1.3	30
124	A Pilot Study to Evaluate 3- <sup>2</sup> -Deoxy-3- <sup>18</sup> F-Fluorothymidine PET for Initial and Early Response Imaging in Mantle Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1898-1902.	5.0	29
125	The lymphoma-like polychemotherapy regimen -Dexa-BEAM-in advanced and extramedullary multiple myeloma. <i>Annals of Hematology</i> , 2014, 93, 1207-1214.	1.8	29
126	Is the Image Quality of I-124-PET Impaired by an Automatic Correction of Prompt Gammas?. <i>PLoS ONE</i> , 2013, 8, e71729.	2.5	28



#	ARTICLE	IF	CITATIONS
127	Fusion of freehand SPECT and ultrasound: First experience in preoperative localization of sentinel lymph nodes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2304-2312.	6.4	28
128	Targeting Paraprotein Biosynthesis for Non-Invasive Characterization of Myeloma Biology. <i>PLoS ONE</i> , 2013, 8, e84840.	2.5	28
129	Use of integrated FDG-PET/CT in sarcoidosis. <i>Clinical Imaging</i> , 2008, 32, 269-273.	1.5	27
130	iROLL: does 3-D radioguided occult lesion localization improve surgical management in early-stage breast cancer?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1692-1699.	6.4	26
131	Predictive Value of <sup>18</sup> F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with Vandetanib. <i>Journal of Nuclear Medicine</i> , 2018, 59, 756-761.	5.0	26
132	<sup>123</sup> I-ITdU-Mediated Nanoirradiation of DNA Efficiently Induces Cell Kill in HL60 Leukemia Cells and in Doxorubicin-, $\alpha$ -, or $\beta$ -Radiation-Resistant Cell Lines. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1000-1007.	5.0	25
133	Potential influence of concomitant chemotherapy on CXCR4 expression in receptor directed endoradiotherapy. <i>British Journal of Haematology</i> , 2019, 184, 440-443.	2.5	25
134	<sup>18</sup> F-FDG and <sup>11</sup> C-Methionine PET/CT in Newly Diagnosed Multiple Myeloma Patients: Comparison of Volume-Based PET Biomarkers. <i>Cancers</i> , 2020, 12, 1042.	3.7	24
135	[ <sup>11</sup> C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1861-1868.	6.4	23
136	Prognostic value of [ <sup>18</sup> F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1694-1704.	6.4	23
137	Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL. <i>Oncotarget</i> , 2014, 5, 4050-4059.	1.8	23
138	Performance of cone beam computed tomography in comparison to conventional imaging techniques for the detection of bone invasion in oral cancer. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2015, 44, 8-15.	1.5	22
139	Nicotinic Acetylcholine Receptor Density in Cognitively Intact Subjects at an Early Stage of Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 213.	3.4	21
140	Nicotinic $\alpha$ 2 acetylcholine receptors and cognitive function in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2014, 130, 164-171.	2.1	21
141	Hexokinase-2 Expression in <sup>11</sup> C-Methionine-Positive, <sup>18</sup> F-FDG-Negative Multiple Myeloma. <i>Journal of Nuclear Medicine</i> , 2019, 60, 348-352.	5.0	21
142	Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. <i>Clinical and Translational Radiation Oncology</i> , 2020, 22, 29-32.	1.7	20
143	Prospective Evaluation of Factors Influencing Success Rates of Sentinel Node Biopsy in 814 Breast Cancer Patients. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 784-790.	1.0	19
144	Synthesis and evaluation of a radiometal-labeled macrocyclic chelator-derivatised thymidine analog. <i>Nuclear Medicine and Biology</i> , 2006, 33, 359-366.	0.6	19

#	ARTICLE	IF	CITATIONS
145	Improved synthesis of [ <sup>18</sup> F]FS-PTAD as a new tyrosine-specific prosthetic group for radiofluorination of biomolecules. <i>Applied Radiation and Isotopes</i> , 2015, 104, 136-142.	1.5	19
146	Integrated FDG-PET-CT: its role in the assessment of bone and soft tissue tumors. <i>Archives of Orthopaedic and Trauma Surgery</i> , 2010, 130, 819-827.	2.4	18
147	Recent advances in radiotracers targeting norepinephrine transporter: structural development and radiolabeling improvements. <i>Journal of Neural Transmission</i> , 2020, 127, 851-873.	2.8	18
148	CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas. <i>Diagnostics</i> , 2021, 11, 605.	2.6	18
149	Targeting CXCR4 with [ <sup>68</sup> Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?. <i>Oncotarget</i> , 2017, 8, 96732-96737.	1.8	17
150	PET Imaging with [ <sup>68</sup> Ga]NOTA-RGD for Prostate Cancer: A Comparative Study with [ <sup>18</sup> F]Fluorodeoxyglucose and [ <sup>18</sup> F]Fluoroethylcholine. <i>Current Cancer Drug Targets</i> , 2014, 14, 371-379.	1.6	17
151	Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [ <sup>68</sup> Ga]Ga-Pentixafor PET/CT. <i>Molecular Imaging and Biology</i> , 2022, 24, 659-665.	2.6	17
152	<sup>18</sup> F-FDG, <sup>11</sup> C-Methionine, and <sup>68</sup> Ga-Pentixafor PET/CT in Patients with Smoldering Multiple Myeloma: Imaging Pattern and Clinical Features. <i>Cancers</i> , 2020, 12, 2333.	3.7	16
153	Value of PET imaging for radiation therapy. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1-23.	2.0	16
154	Investigation of spleen CXCR4 expression by [ <sup>68</sup> Ga]Pentixafor PET in a cohort of 145 solid cancer patients. <i>EJNMMI Research</i> , 2021, 11, 77.	2.5	16
155	The impact of <sup>177</sup> Lu-octreotide therapy on <sup>99m</sup> Tc-MAG3 clearance is not predictive for late nephropathy. <i>Oncotarget</i> , 0, 7, 41233-41241.	1.8	16
156	PET/CT for staging lung cancer: costly or cost-saving?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 799-801.	6.4	15
157	[ <sup>68</sup> Ga]Pentixafor-Positron Emission Tomography/Computed Tomography Detects Chemokine Receptor CXCR4 Expression After Ischemic Stroke. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, e005217.	2.6	15
158	Cholinergic activity and levodopa-induced dyskinesia: a multitracer molecular imaging study. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 632-639.	3.7	15
159	[ <sup>68</sup> Ga]-Pentixafor PET/CT for CXCR4-Mediated Imaging of Vestibular Schwannomas. <i>Frontiers in Oncology</i> , 2019, 9, 503.	2.8	15
160	Short Communication: <sup>18</sup> F-Immuno-PET: Determination of Anti-CD66 Biodistribution in a Patient with High-Risk Leukemia. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2008, 23, 819-824.	1.0	14
161	Performance of Integrated FDG-PET/CT for Differentiating Benign and Malignant Lung Lesions -Results from a Large Prospective Clinical Trial. <i>Molecular Imaging and Biology</i> , 2008, 10, 121-128.	2.6	13
162	Functional Imaging of Pheochromocytoma with <sup>68</sup> Ga-DOTATOC and <sup>68</sup> C-HED in a Genetically Defined Rat Model of Multiple Endocrine Neoplasia. <i>International Journal of Molecular Imaging</i> , 2011, 2011, 1-9.	1.3	13

#	ARTICLE	IF	CITATIONS
163	PET Tracers in Musculoskeletal Disease beyond FDG. <i>Seminars in Musculoskeletal Radiology</i> , 2014, 18, 123-132.	0.7	13
164	Three-Phase Bone Scintigraphy for Imaging Osteoradionecrosis of the Jaw. <i>Clinical Nuclear Medicine</i> , 2014, 39, 21-25.	1.3	13
165	[ <sup>11</sup> C]Methionine emerges as a new biomarker for tracking active myeloma lesions. <i>British Journal of Haematology</i> , 2018, 181, 701-703.	2.5	13
166	Chemokine Receptor 4 Expression in Primary Sjögren's Syndrome. <i>Clinical Nuclear Medicine</i> , 2018, 43, 835-836.	1.3	13
167	<sup>68</sup> Ga-Pentixafor PET/CT for Detection of Chemokine Receptor CXCR4 Expression in Myeloproliferative Neoplasms. <i>Journal of Nuclear Medicine</i> , 2022, 63, 96-99.	5.0	13
168	Antifungal Therapy with Itraconazole Impairs the Anti-Lymphoma Effects of Rituximab by Inhibiting Recruitment of CD20 to Cell Surface Lipid Rafts. <i>Cancer Research</i> , 2010, 70, 4292-4296.	0.9	12
169	Relationship Between Antithyroglobulin Autoantibodies and Thyroglobulin Recovery Rates Using Different Thyroglobulin Concentrations in the Recovery Buffer. <i>Hormone and Metabolic Research</i> , 2013, 45, 728-735.	1.5	12
170	Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management. <i>Frontiers in Endocrinology</i> , 2021, 12, 643328.	3.5	12
171	Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphoma. <i>OncoTargets and Therapy</i> , 2014, 7, 789.	2.0	11
172	Proliferation Imaging with 18F-Fluorothymidine PET/Computed Tomography. <i>PET Clinics</i> , 2014, 9, 331-338.	3.0	11
173	The gross picture: intraindividual tumour heterogeneity in a patient with nonsecretory multiple myeloma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1097-1098.	6.4	11
174	Peptide receptor radionuclide therapy as a new tool in treatment-refractory sarcoidosis - initial experience in two patients. <i>Theranostics</i> , 2018, 8, 644-649.	10.0	11
175	Integrated FDG PET-CT imaging improves staging in malignant pleural mesothelioma. <i>Nuklearmedizin - Nuclear Medicine</i> , 2007, 46, 239-43.	0.7	11
176	Intraindividual tumor heterogeneity in NET – Further insight by C-X-C motif chemokine receptor 4-directed imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 553-554.	6.4	10
177	Anti-Inflammatory Effects on Atherosclerotic Lesions Induced by CXCR4-Directed Endoradiotherapy. <i>Journal of the American College of Cardiology</i> , 2018, 72, 122-123.	2.8	10
178	Molecular imaging for early prediction of response to Sorafenib treatment in sarcoma. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 4, 70-9.	1.0	10
179	Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy. <i>EJNMMI Research</i> , 2014, 4, 74.	2.5	9
180	Human Organotypic Lung Tumor Models: Suitable For Preclinical 18F-FDG PET-Imaging. <i>PLoS ONE</i> , 2016, 11, e0160282.	2.5	9

#	ARTICLE	IF	CITATIONS
181	Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy. <i>EJNMMI Research</i> , 2014, 4, 46.	2.5	8
182	Assessment of tumor heterogeneity in treatment-naïve adrenocortical cancer patients using 18F-FDG positron emission tomography. <i>Endocrine</i> , 2016, 53, 791-800.	2.3	8
183	18F-fluorothymidine PET for predicting survival in patients with resectable pancreatic cancer. <i>Oncotarget</i> , 2018, 9, 10128-10134.	1.8	8
184	Peptide Receptor Radionuclide Therapy for Sarcoidosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1428-1430.	5.6	7
185	Prognostic Value of O-(2-[18F]Fluoroethyl)-L-Tyrosine PET/CT in Newly Diagnosed WHO 2016 Grade II and III Glioma. <i>Molecular Imaging and Biology</i> , 2019, 21, 1174-1181.	2.6	7
186	Novel CYP11B-ligand [123/131]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, , 1.	6.4	7
187	Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma. <i>British Journal of Haematology</i> , 2022, 198, 515-522.	2.5	7
188	Visualization of Tumor Heterogeneity in Advanced Medullary Thyroid Carcinoma by Dual-Tracer Molecular Imaging. <i>Clinical Nuclear Medicine</i> , 2022, 47, 651-652.	1.3	6
189	Impact of aging on semiquantitative uptake parameters in normal rated clinical baseline [123I]Ioflupane single photon emission computed tomography/computed tomography. <i>Nuclear Medicine Communications</i> , 2019, 40, 1001-1004.	1.1	5
190	Targeting 11-Beta Hydroxylase With [131I]IMAZA: A Novel Approach for the Treatment of Advanced Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1348-e1355.	3.6	5
191	Somatostatin receptor-directed molecular imaging for therapeutic decision-making in patients with medullary thyroid carcinoma. <i>Endocrine</i> , 2022, 78, 169-176.	2.3	5
192	Pretherapeutic estimation of kidney function in patients treated with peptide receptor radionuclide therapy. <i>Nuclear Medicine Communications</i> , 2014, 35, 1143-1149.	1.1	4
193	Small-Animal PET Imaging of Isolated Perfused Rat Heart. <i>Journal of Nuclear Medicine</i> , 2014, 55, 495-499.	5.0	4
194	The Link between Cytogenetics/Genomics and Imaging Patterns of Relapse and Progression in Patients with Relapsed/Refractory Multiple Myeloma: A Pilot Study Utilizing 18F-FDG PET/CT. <i>Cancers</i> , 2020, 12, 2399.	3.7	4
195	Assessment of disease activity in alveolar echinococcosis: a comparison of contrast enhanced ultrasound, three-phase helical CT and [18F] fluorodeoxyglucose positron emission tomography. <i>Abdominal Imaging</i> , 2007, 32, 730.	2.0	4
196	Responsivity of the Striatal Dopamine System to Methylphenidate—A Within-Subject I-123-Î²-CIT-SPECT Study in Male Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. <i>Frontiers in Psychiatry</i> , 2022, 13, 804730.	2.6	4
197	Elevated FDG Uptake in the Lactating Human Breast. <i>Clinical Nuclear Medicine</i> , 2001, 26, 577-578.	1.3	3
198	Staging of Non-Small-Cell Lung Cancer with Integrated PET and CT. <i>New England Journal of Medicine</i> , 2003, 349, 1188-1190.	27.0	3

#	ARTICLE	IF	CITATIONS
199	Chromosome instability and tumor lethality suppression in carcinogenesis. <i>Journal of Cellular Biochemistry</i> , 2008, 105, 1327-1341.	2.6	3
200	Alternative PET Tracers in Musculoskeletal Disease. <i>PET Clinics</i> , 2010, 5, 363-374.	3.0	3
201	Primary bone marrow diffuse large B-cell lymphoma affecting distal parts of the legs as a cause of persisting B symptoms. <i>European Journal of Haematology</i> , 2014, 93, 545-546.	2.2	3
202	Early development of a celiac trunk aneurysm during anti-vascular endothelial growth factor receptor therapy. <i>Surgery</i> , 2014, 155, 729-730.	1.9	3
203	Evidence of impaired carbohydrate assimilation in euthyroid patients with Hashimoto's thyroiditis. <i>European Journal of Clinical Nutrition</i> , 2016, 70, 222-228.	2.9	3
204	Adrenal functional imaging. <i>Presse Medicale</i> , 2022, 51, 104114.	1.9	3
205	Navigated nuclear probes for intra-operative functional imaging. , 2008, , .		2
206	Reply: SPECT/CT. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1009.2-1010.	5.0	2
207	Melanoma Metastases to Palatine Tonsils Obscured by Physiological FDG Uptake on PET/CT. <i>Clinical Nuclear Medicine</i> , 2010, 35, 101-102.	1.3	2
208	Pancreatic and Hepatobiliary Cancers. <i>Methods in Molecular Biology</i> , 2011, 727, 243-264.	0.9	2
209	<sup>18</sup> F-fluorothymidine uptake in follicular lymphoma and error-prone DNA repair. <i>EJNMMI Research</i> , 2014, 4, 3.	2.5	2
210	Diagnostic Findings and Treatment in a 51-Year-Old Woman With Oncogenic Osteomalacia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 385-386.	3.6	2
211	Value of PET imaging for radiation therapy. <i>Nuklearmedizin - NuclearMedicine</i> , 2021, 60, 326-343.	0.7	2
212	Molecular Imaging in Multiple Myeloma – Novel PET Radiotracers Improve Patient Management and Guide Therapy. <i>Frontiers in Nuclear Medicine</i> , 2022, 2, .	1.2	2
213	The Number of Frames on ECG-Gated <sup>18</sup> F-FDG Small Animal PET Has a Significant Impact on LV Systolic and Diastolic Functional Parameters. <i>Molecular Imaging</i> , 2021, 2021, 1-8.	1.4	2
214	Synthesis and biodistribution of <sup>3</sup> fluoro-5-[ <sup>131</sup> I]iodo-2-deoxyuridine: a comparative study of [ <sup>131</sup> I]FLIdU and [ <sup>18</sup> F]FLT. <i>Nuclear Medicine and Biology</i> , 2007, 34, 273-281.	0.6	1
215	Demonstration of metastatic tumour growth following vessel structures by PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1021-1021.	6.4	1
216	PET/CT with <sup>18</sup> F-FLT Is Unlikely to Cause Significant Hepatorenal or Hematologic Toxicity. <i>Journal of Nuclear Medicine</i> , 2010, 51, 824.2-825.	5.0	1

#	ARTICLE	IF	CITATIONS
217	Paralytic Subileus as an Adverse Effect of Amino Acid-Based Nephroprotection in a Patient Undergoing Peptide Receptor Radionuclide Therapy. <i>Clinical Nuclear Medicine</i> , 2015, 40, 263-264.	1.3	1
218	Thyroid incidentalomas with increased focal 18F-FDG uptake in 18F-FDG PET/CT of a patient with multiple primary cancers.. <i>Endocrine</i> , 2021, 73, 491-492.	2.3	1
219	Preclinical Evaluation of CD40-Directed Immunotherapy in B-Cell Lymphoma Using [ <sup>18</sup> F]Fluorothymidine-PET. <i>Advances in Molecular Imaging</i> , 2015, 05, 17-28.	0.3	1
220	Radiosynthesis and evaluation of [11C]BTA-1 and [11C]3'-Me-BTA-1 as potential radiotracers for in vivo imaging of-amyloid plaques. <i>Nuklearmedizin - NuclearMedicine</i> , 2007, , .	0.7	1
221	Gastroesophageal Cancer. , 2018, , 65-84.		0
222	Pulmonary vasculitis due to infection with <i>Mycobacterium goodii</i> : A case report. <i>International Journal of Infectious Diseases</i> , 2021, 104, 178-180.	3.3	0
223	[18F]FLT Is Superior to [18F]FDG to Early Predict Response to Specific Inhibitors of NPM-ALK-Dependent Pathways In a Human ALCL Xenograft Model. <i>Blood</i> , 2010, 116, 2849-2849.	1.4	0
224	FLT PET/CT-Guided Biopsy in the Evaluation of Cancer. , 2016, , 65-76.		0
225	T-Staging and Target Volume Definition by Imaging in GI Tumors. <i>Medical Radiology</i> , 2020, , 203-220.	0.1	0
226	PET Imaging of Breast Cancer Molecular Biomarkers. , 2008, , 145-156.		0
227	Real-World Experience with Minimal Residual Disease Testing with Next Generation Flow Cytometry and Functional Imaging in Multiple Myeloma. <i>Blood</i> , 2020, 136, 17-18.	1.4	0
228	Secondary Biphenotypic Acute Leukemia Following Rosai-Dorfman-Disease A Coincidence?. <i>Klinische Padiatrie</i> , 2021, , .	0.6	0
229	CXCR4 expression of multiple myeloma as a dynamic process: influence of therapeutic agents. <i>Leukemia and Lymphoma</i> , 0, , 1-10.	1.3	0